T. Rowe Price Associates (CLDX) discloses 6.0% Celldex Therapeutics ownership on Schedule 13G
T. Rowe Price Associates, Inc. filed a Schedule 13G reporting beneficial ownership of Celldex Therapeutics Inc. common stock. It reported 4,686,187 shares, or 6.0% of the class, with sole voting power over 4,683,226 shares and sole dispositive power over 4,686,187 shares, according to the filing.
How this was made
The 30-second read
Why it matters
For CLDX, the actionable takeaway is the disclosed ownership level (6.0%) and the reported sole voting and dispositive powers, which can matter for ownership tracking but not necessarily for near-term fundamentals.
Market read
This is a fresh ownership disclosure for CLDX, useful for tracking institutional positioning but lacking a direct operational or event-driven catalyst.
What to watch
The article does not specify whether the position is newly initiated versus previously held, nor does it provide any intent to pursue governance changes.
Background
The article summarizes a Schedule 13G filing in which T. Rowe Price Associates reports beneficial ownership of Celldex Therapeutics common stock.
Ticker impact
T. Rowe Price Associates filed a Schedule 13G reporting 4,686,187 Celldex shares, or 6.0% of the class.
Likely limited immediate price impact; any effect would be gradual via sentiment around institutional accumulation.
Schedule 13G is typically passive/investment intent and the article provides no catalyst beyond the disclosed stake size and voting/dispositive powers.
Market effects
Minimal; this is an ownership disclosure rather than a clinical, regulatory, or product catalyst for biotech.
None indicated.
None indicated.
Counterpoint
A 6% stake can still be consistent with passive investment, so the market may overreact to the headline without any control implications.
Key entities
- issuerCelldex Therapeutics Inc.
Reported beneficial ownership by T. Rowe Price Associates of 4,686,187 shares, 6.0% of the class, via Schedule 13G.
- investorT. Rowe Price Associates, Inc.
Filed the Schedule 13G reporting sole voting power over 4,683,226 shares and sole dispositive power over 4,686,187 shares.
